Skip to main content

Table 2 Comparison of the mean VAS scores, MNMA, MAC, and MNHD in the GONB + PRF group at the 1-, 2-, 3-, and 6-month follow-up assessments

From: Effectiveness of combining greater occipital nerve block and pulsed radiofrequency treatment in patients with chronic migraine: a double-blind, randomized controlled trial

 

Timepoint

Mean difference

P value

VAS

Baseline (8.63)

1st month (3.69)

4.94*

< 0.001b

Baseline (8.63)

2nd month (3.31)

5.313*

< 0.001b

Baseline (8.63)

3rd month (2.75)

5.875*

< 0.001b

Baseline (8.63)

6th month (3.50)

5.125*

< 0.001b

MNMA

Baseline (9.6)

1st month (1.94)

7.63*

< 0.001b

Baseline (9.6)

2nd month (1.31)

8.25*

< 0.001b

Baseline (9.6)

3rd month (1.06)

8.5*

< 0.001b

Baseline (9.6)

6th month (1.56)

8*

< 0.001b

MAC

Baseline (9.95)

1st month (1.9)

8.05*

< 0.001b

Baseline (9.95)

2nd month (1.2)

8.75*

< 0.001b

Baseline (9.95)

3rd month (1.06)

8.9*

< 0.001b

Baseline (9.95)

6th month(1.63)

8,32*

< 0.001b

MNHD

Baseline (16.56)

1st month (3.06)

13.5*

< 0.001b

Baseline (16.56)

2nd month (3)

13.56*

< 0.001b

Baseline (16.56)

3rd month (3.25)

13.3*

< 0.001b

Baseline (16.56)

6th month (3.44)

13.12*

< 0.001b

  1. *The mean difference is significant at the 0.05 level.
  2. bAdjustment for multiple comparisons: Bonferroni.
  3. *P < 0.05 (95% confidence intervals).
  4. GONB + PRF, greater occipital nerve block combined with pulsed radiofrequency; VAS, visual analog scale; MNMA, mean number of migraine attacks; MAC, mean analgesic consumption; MNHD, mean number of headache days.